Are research peptides actually dangerous gray-market drugs?

What's this video probably claiming?

Based on the caption, @dr.tommymartin is making two core arguments: that FDA non-approval is itself evidence a peptide doesn't work, and that the "research use only" label is essentially a consumer warning in disguise. He's likely extending this to the full peptide category the hashtags point to, including BPC-157, TB-500, CJC-1295, ipamorelin, GHK-Cu, MK-677, semax, and selank. The implied conclusion is probably that anyone using these compounds is taking an unjustified risk on substances that haven't earned clinical legitimacy. That's a defensible position on its face, but it collapses when you examine it closely. FDA approval status and clinical evidence are not the same thing. Conflating them is a rhetorical move, not a scientific argument. The creator may also be implying that compounded peptides from licensed pharmacies carry the same risk profile as gray-market research chemicals, which would be a meaningful and misleading distinction to skip over.

What does the science actually show?

The evidence base for this peptide category is genuinely uneven, and that's worth saying plainly. BPC-157 has a substantial rodent literature, including work by Sikiric et al. published repeatedly in Current Pharmaceutical Design and Journal of Physiology-Paris, showing accelerated tendon and gut healing in animal models. But there are no completed Phase III human trials. TB-500 (thymosin beta-4) has similarly promising preclinical data on tissue repair, with Goldstein and colleagues documenting its actin-sequestering mechanism in human cells, but again, no large randomized controlled trials in people. CJC-1295 and ipamorelin do have human pharmacokinetic data. Teichman et al. (2006, Journal of Clinical Endocrinology and Metabolism) showed CJC-1295 raised IGF-1 levels by 28-43% at doses of 30-60 mcg/kg in healthy adults. MK-677 has the most strong human data of this group, with Nass et al. (2008, Journal of Clinical Endocrinology and Metabolism) demonstrating sustained GH pulse increases over 12 months. The honest picture: some of these have real mechanistic and early clinical data. Others are running almost entirely on animal studies and anecdote.

Where does the social media noise diverge from clinical reality?

Two divergences stand out. First, peptide advocates on TikTok and Instagram routinely present animal study findings as if they translate directly to humans at equivalent doses, which is not how pharmacology works. A 250 mcg/kg dose that repairs a rat's Achilles tendon tells you something interesting, not something actionable for a 180-pound person. Second, and this is where the creator's argument also goes wrong, critics like @dr.tommymartin often treat "not FDA-approved" as synonymous with "no evidence and not safe." Metformin was used clinically in Europe for decades before FDA approval. Plenty of off-label prescribing of FDA-approved drugs happens daily in American medicine with solid evidence behind it. The actual risk signal for peptides isn't primarily the approval status. It's the sourcing. A 2020 analysis by Cohen et al. in JAMA Internal Medicine found that 9 of 14 tested "research peptide" products contained wrong doses or unlisted compounds. That's the real problem: supply chain integrity, not the peptide class itself when obtained through a licensed compounding pharmacy operating under USP standards.

What should you actually know?

The creator isn't entirely wrong, but the argument is too blunt to be useful. Here's what the evidence actually supports. First, peptides obtained from unregulated online vendors carry real contamination and misdosing risks that have nothing to do with the peptide's intrinsic pharmacology. Second, some peptides in this category, particularly the GHRH/GHRP class like CJC-1295 and ipamorelin, have enough human data to support supervised clinical use, while others like semax and selank have almost no peer-reviewed English-language human data at all. Third, the FDA regulatory pathway exists for drugs targeting specific disease indications with large enough markets to justify Phase III trial costs. It was never designed to capture every biologically active compound with legitimate therapeutic potential. Patients using these compounds through a licensed telehealth provider and a 503A or 503B compounding pharmacy are operating in a different risk environment than someone injecting an unlabeled vial ordered from a research chemical site. That distinction matters, and flattening it misleads the people most likely to be watching this video.